Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 10/20 | 0.73 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.73 |
| ▸ | REN | P00797 | 2/20 | 0.68 |
| ▸ | LNPEP | Q9UIQ6 | 2/20 | 0.58 |
| ▸ | RAMP3 | O60896 | 1/20 | 0.57 |
| ▸ | CALCR | P30988 | 1/20 | 0.57 |
| ▸ | NPY1R | P25929 | 1/20 | 0.57 |
| ▸ | NPY2R | P49146 | 1/20 | 0.57 |
| ▸ | NPY4R | P50391 | 1/20 | 0.57 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Angiotensin Amide SCHEMBL9324 | 0.99 | AGTR2 (0.74) | AGTR2AGTR1RENLNPEPNPY1R | |
| Angiotensin Amide SCHEMBL8155919 | 0.99 | AGTR2 (0.74) | AGTR2AGTR1RENLNPEPNPY1R | |
| Angiotensin Amide SCHEMBL9433448 | 0.98 | AGTR2 (0.73) | AGTR2AGTR1RENLNPEPNPY1R | |
| Angiotensin Amide SCHEMBL7337886 | 0.98 | AGTR2 (0.73) | AGTR2AGTR1RENLNPEPNPY1R | |
| Angiotensin Amide SCHEMBL10495835 | 0.97 | AGTR2 (0.72) | AGTR2AGTR1RENLNPEPNPY1R | |
| Angiotensin Amide SCHEMBL23015107 | 0.97 | AGTR2 (0.71) | AGTR2AGTR1RENLNPEPNPY1R | |
| Angiotensin Amide SCHEMBL3850850 | 0.97 | AGTR2 (0.71) | AGTR2AGTR1RENLNPEPNPY1R | |
| Angiotensin Amide SCHEMBL5722115 | 0.96 | AGTR2 (0.75) | AGTR2AGTR1RENNPY1RNPY2R | |
| Angiotensin Amide SCHEMBL9023554 | 0.94 | AGTR2 (0.68) | AGTR2AGTR1RENNPY1RNPY2R | |
| Angiotensin Ii SCHEMBL513519 | 0.94 | AGTR2 (0.82) | AGTR2AGTR1RENLNPEPNPY1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680263-B2 | Carbohydrate-based drug delivery polymers and conjugates thereof | NEKTAR THERAPEUTICS (US) | 2014-03-25 | — | — | US | disclosed |
| US-20110171716-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | NEKTAR THERAPEUTICS (US) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110171716-A1 | CARBOHYDRATE-BASED DRUG DELIVERY POLYMERS AND CONJUGATES THEREOF | STT3B, STT3A, DDOST | AGTR2 3547/4885AGTR1 3279/4885REN 1890/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.